| Event | During ACCORD-lipid (short-term effect) | P | Post-trial only (legacy effect) | P | Full follow-up (long-term effect) | P |
|---|
| Rate of events (100 person-years) | Hazard Ratio (95% CI) | Rate of events (100 person-years) | Hazard ratio (95% CI) | Rate of events (100 person-years) | Hazard ratio (95% CI) |
|---|
| Fibrate | Placebo | Fibrate | Placebo | Fibrate | Placebo |
|---|
| All-cause mortality | 1.54 | 2.26 | 0.68 (0.44, 1.04) | 0.07 | 3.05 | 4.43 | 0.65 (0.45, 0.94) | 0.02 | 2.23 | 3.24 | 0.68 (0.52, 0.88) | < 0.01 |
| CVD mortality | 0.67 | 1.28 | 0.53 (0.29, 0.98) | 0.04 | 1.12 | 1.53 | 0.77 (0.43, 1.39) | 0.38 | 0.88 | 1.39 | 0.63 (0.42, 0.95) | 0.03 |
| Nonfatal MI | 1.76 | 2.45 | 0.72 (0.47, 1.09) | 0.12 | 0.85 | 1.07 | 0.74 (0.33, 1.66) | 0.47 | 1.40 | 1.91 | 0.74 (0.51, 1.06) | 0.10 |
| Stroke | 0.56 | 0.74 | 0.75 (0.36, 1.56) | 0.44 | 0.56 | 0.55 | 0.87 (0.33, 2.29) | 0.78 | 0.58 | 0.67 | 0.88 (0.5, 1.56) | 0.66 |
| CHF | 1.39 | 1.51 | 0.90 (0.55, 1.47) | 0.68 | 0.65 | 0.93 | 0.69 (0.30, 1.57) | 0.38 | 1.07 | 1.27 | 0.82 (0.54, 1.24) | 0.35 |
| Major CHD | 3.01 | 4.60 | 0.65 (0.48, 0.90) | 0.01 | 2.17 | 3.27 | 0.64 (0.40, 1.03) | 0.07 | 2.67 | 4.09 | 0.66 (0.51, 0.86) | < 0.01 |
- MI myocardial infarction, CHF congestive heart failure, CHD coronary heart disease
